Wall Street analyst estimates for Citius Pharmaceuticals, Inc. (CTXR): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-12-22 | $-0.41 | ||
| 2026-12-17 | $-0.41 | ||
| 2026-08-14 | $-0.34 | $-0.36 | +5.6% |
| 2026-05-15 | $-0.95 | $-0.28 | -238.4% |
| 2026-02-13 | $-0.38 | $0.43 | -188.4% |
| 2025-12-26 | $-0.01 | $-0.43 | +97.7% |
| 2025-08-12 | $-0.80 | $-0.51 | -58.4% |
| 2025-05-14 | $-1.27 | $-1.08 | -17.6% |
Valuation Ratios
| Price / Book | 0.21 |
| EV / EBITDA | 0.06 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $1343 | $2632 | $1753 | $893 | $152364 | $164868 | 0 | 0 | $209611 | $214250 |
| Gross Profit | -$1343 | -$2632 | -$1753 | -$893 | -$152364 | -$164868 | 0 | 0 | -$209611 | -$214250 |
| Research & Development | $2.9M | $2.9M | $6.6M | $8.6M | $8.8M | $12.2M | $17.7M | $14.8M | $11.9M | $9.2M |
| Selling, General & Admin | $4.5M | $7.1M | $7.2M | $7.0M | $8.7M | $11.1M | $15.7M | $21.9M | $18.2M | $18.5M |
| Operating Expenses | $7.4M | $10.0M | $13.8M | $15.6M | $17.6M | $23.4M | $33.3M | $36.7M | $42.0M | $38.3M |
| Operating Income | -$7.4M | -$10.0M | -$13.8M | -$15.6M | -$17.7M | -$23.5M | -$33.3M | -$36.7M | -$42.0M | -$38.5M |
| EBITDA | -$7.4M | -$10.0M | -$13.8M | -$15.5M | -$17.6M | -$23.4M | -$33.1M | -$36.5M | -$38.6M | -$38.2M |
| Interest Expense | $8994 | $850789 | $15838 | $16443 | $15673 | $10839 | 0 | 0 | 0 | $267782 |
| Pre-tax Income | -$8.3M | -$10.4M | -$12.5M | -$15.6M | -$17.5M | -$23.1M | -$33.1M | -$32.0M | -$38.8M | -$38.7M |
| Income Tax | $8994 | 0 | 0 | $16443 | 0 | 0 | $576000 | $576000 | $576000 | $1.1M |
| Net Income | -$8.3M | -$10.4M | -$12.5M | -$15.6M | -$17.5M | -$23.1M | -$33.6M | -$32.5M | -$39.1M | -$37.4M |
| EPS | $-2.29 | $-1.89 | $-1.17 | $-0.77 | $-11.20 | $-5.64 | $-5.75 | $-5.57 | $-5.97 | $-3.38 |
| EPS (Diluted) | $-2.29 | $-1.89 | $-1.17 | $-0.77 | $-11.20 | $-5.64 | $-5.75 | $-5.57 | $-5.97 | $-3.38 |
| Shares Outstanding (Diluted) | $241547 | $365500 | $715458 | $1.3M | $1.6M | $4.3M | $5.8M | $6.1M | $11.6M | $11.1M |
Price
| Price | $0.56 |
| Market Cap | $6M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ADTX · APLM · ATHA · CRIS · DARE · FBLG · ICU
Explore sector: Healthcare · Biotechnology
More sections of CTXR: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks